Zobrazeno 1 - 10
of 610
pro vyhledávání: '"Ho-Yeong Lim"'
Autor:
Chia-Jui Yen, Masatoshi Kudo, Ho-Yeong Lim, Chih-Hung Hsu, Arndt Vogel, Giovanni Brandi, Rebecca Cheng, Ioana Simona Nitu, Paolo Abada, Yanzhi Hsu, Andrew X. Zhu, Yoon-Koo Kang
Publikováno v:
Liver Cancer, Pp 1-15 (2020)
Objective: REACH-2 and REACH were randomized, placebo-controlled, double-blind, multicenter phase 3 trials which showed survival benefits of ramucirumab treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein
Externí odkaz:
https://doaj.org/article/56325c9739d2463abfb71dbe7e992f0a
Autor:
Hye Ryeon Kim, Soomin Ahn, Hyunji Jo, Hongsik Kim, Joohyun Hong, Jeeyun Lee, Ho-Yeong Lim, Won Ki Kang, Seung Tae Kim
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundTrastuzumab is a HER2-trargeted humanized monoclonal antibody that has been studied as a first-line treatment for patients with HER2-positive advanced gastric cancer (AGC). The effect of anti-HER2 therapy according to tumor mutational burde
Externí odkaz:
https://doaj.org/article/3aabafd8b49749279f87e8b796907259
Autor:
Sojung Han, Do Young Kim, Ho Yeong Lim, Jung-Hwan Yoon, Baek-Yeol Ryoo, Yujeong Kim, Kookhee Kim, Bo Yeon Kim, So Young Yi, Dong-Sook Kim, Do-Yeon Cho, Jina Yu, Suhyun Kim, Joong-Won Park
Publikováno v:
Gut and Liver, Vol 18, Iss 1, Pp 116-124 (2024)
Background/Aims: Sorafenib is the standard of care in the management of advanced hepatocellular carcinoma (HCC). The purpose of this study was to investigate the characteristics, treatment patterns and outcomes of sorafenib among HCC patients in Sout
Externí odkaz:
https://doaj.org/article/785dff6945e744c09e895390ae02284a
Autor:
Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Francesca Bergamo, Elisabeth Amadeo, Francesco Vitiello, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Massimo Iavarone, Giuseppe Cabibbo, Margarida Montes, Francesco Giuseppe Foschi, Caterina Vivaldi, Caterina Soldà, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Hiraoka, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Mara Persano, Silvia Foti, Silvia Camera, Bernardo Stefanini, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini, Margherita Rimini
Publikováno v:
Liver Cancer (2024)
Introduction The impact of etiology on response to immunotherapy in advanced hepatocellular carcinoma (HCC) is being debated, with contrasting findings between early and recent post-hoc analyses of IMbrave-150 and metanalyses of clinical trials of PD
Externí odkaz:
https://doaj.org/article/3da67a4e9b81471598019e46c12fc527
Autor:
Shukui Qin, Weijia Fang, Zhenggang Ren, Shuangyan Ou, Ho Yeong Lim, Feng Zhang, Kin Chung Lee, Hye Jin Choi, Jiandong Tong, Min Tao, Aibing Xu, Ashley Cheng, Chang-Hsien Lu, Chang-Fang Chiu, Mohamed Ibrahim Abdul Wahid, Shital Kamble, Josephine M. Norquist, Wenyan Zhong, Chen Li, Zhendong Chen
Publikováno v:
Liver Cancer (2024)
Introduction KEYNOTE-394 showed pembrolizumab significantly improved overall survival, progression-free survival, and objective response rate with manageable safety versus placebo for patients from Asia with previously treated advanced hepatocellular
Externí odkaz:
https://doaj.org/article/af000c83c7e94d4da9def0a30952f917
Autor:
Nalee Kim, Jeong Il Yu, Hee Chul Park, Jung Yong Hong, Ho Yeong Lim, Myung Ji Goh, Yong-Han Paik
Publikováno v:
Journal of Liver Cancer, Vol 23, Iss 2, Pp 350-361 (2023)
Background/Aim Patients with large (>5 cm) hepatocellular carcinoma (HCC) have limited treatment options, thus necessitating the identification of prognostic factors and the development of predictive tools. This study aimed to identify prognostic fac
Externí odkaz:
https://doaj.org/article/bbe0547ad2184a9a89d905555482bd36
Autor:
Sun Young Jeong, Jung Yong Hong, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Jae Yeon Jang, Youngkyung Jeon, Seung Tae Kim
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 16 (2023)
Background: With a 15% incidence, KRAS is one of the most common mutations in biliary tract cancer (BTC) and is a poor prognostic factor. Immune checkpoint inhibitors (ICIs) as salvage therapy have modest activity in BTC. Objectives: There are limite
Externí odkaz:
https://doaj.org/article/0bb07600025f4925b23ab1ee1ce2d3fc
Autor:
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Marcelo Garrido, Jennifer Knox, Bruno Daniele, Valeriy Breder, Ho Yeong Lim, Sadahisa Ogasawara, Stéphane Cattan, Yee Chao, Abby B. Siegel, Iván Martinez-Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn
Publikováno v:
Liver Cancer (2023)
Introduction: KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall surviva
Externí odkaz:
https://doaj.org/article/cd768b0d783a455fbb086706dc35b886
Autor:
Hyung-Don Kim, Seyoung Jung, Ho Yeong Lim, Baek-Yeol Ryoo, Min-Hee Ryu, Hong Jae Chon, Beodeul Kang, Jung Yong Hong, Han Chu Lee, Deok-Bog Moon, Ki-Hoon Kim, Tae Won Kim, Jeong Seok Lee, Richard S. Finn, June-Young Koh, Changhoon Yoo
Regorafenib plus nivolumab (RegoNivo) combination has shown promising anti-cancer activity in multiple cancer types. REBNOBATE trial is a single-arm multicenter phase 2 trial of first-line RegoNivo in patients (pts) with uHCC (NCT04310709). Here we r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e24ad3eff16aefcb685092da825f8c7
Autor:
Jihoon Ko, Jaeyun Jung, Seung Tae Kim, Jung Yong Hong, Sehhoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Soomin Ahn, Kyoung-Mee Kim, Won Ki Kang, Jeeyun Lee
Publikováno v:
Pathology and Oncology Research, Vol 28 (2022)
Background: To aid in oncology drug development, we investigated MET proto-oncogene receptor tyrosine kinase gene aberrations in 2,239 oncology patients who underwent next-generation sequencing (NGS) in clinical practice.Materials and methods: From N
Externí odkaz:
https://doaj.org/article/8a77c40a11f6496c8c69c8e9d5711c38